ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

It comes shortly after AbbVie offered $10.1 billion to buy ImmunoGen and its marketed ovarian cancer drug Elahere (mirvetuximab soravtansine), and a pipeline of other antibody-drug conjugates for ...

Ovarian cancer is a relatively manageable malignancy when diagnosed at an early stage, but late-stage detection almost always translates into a poor prognosis. Researchers have been vigorously ...

PARP inhibitors prevent cancer cells from repairing their DNA. Elahere (molecular name mirvetuximab) is an FDA-approved targeted therapy providing much-needed hope for patients with platinum-resistant ...

patients who may benefit from ELAHERE ; LightCycler PRO System, a qPCR system designed to deliver accuracy and flexibility to research and clinical diagnostic laboratories; and cobas pulse, a ...